These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 7773949)
1. Etoposide, ifosfamide, and cisplatin therapy for refractory childhood solid tumors. Response and toxicity. van Hoff J; Grier HE; Douglass EC; Green DM Cancer; 1995 Jun; 75(12):2966-70. PubMed ID: 7773949 [TBL] [Abstract][Full Text] [Related]
2. Prospective randomized trial between two doses of granulocyte colony-stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent or refractory solid tumors: a children's cancer group report. Cairo MS; Shen V; Krailo MD; Bauer M; Miser JS; Sato JK; Blatt J; Blazar BR; Frierdich S; Liu-Mares W; Reaman GH J Pediatr Hematol Oncol; 2001 Jan; 23(1):30-8. PubMed ID: 11196267 [TBL] [Abstract][Full Text] [Related]
3. Maximum-tolerated doses of ifosfamide, carboplatin, and etoposide given over 6 days followed by autologous stem-cell rescue: toxicity profile. Fields KK; Elfenbein GJ; Lazarus HM; Cooper BW; Perkins JB; Creger RJ; Ballester OF; Hiemenz JH; Janssen WE; Zorsky PE J Clin Oncol; 1995 Feb; 13(2):323-32. PubMed ID: 7844593 [TBL] [Abstract][Full Text] [Related]
4. Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide. Loehrer PJ; Lauer R; Roth BJ; Williams SD; Kalasinski LA; Einhorn LH Ann Intern Med; 1988 Oct; 109(7):540-6. PubMed ID: 2844110 [TBL] [Abstract][Full Text] [Related]
5. A phase II trial of oral etoposide with mitoxantrone and ifosfamide/mesna consolidated with intravenous etoposide, methylprednisolone, high-dose arabinoside, and cisplatin as salvage therapy for relapsing and/or refractory lymphomas. Romaguera JE; Rodriguez MA; Hagemeister FB; McLaughlin P; Swan F; Moore DF; Sarris AH; Younes A; Hill D; Cabanillas F Invest New Drugs; 1994; 12(3):217-22. PubMed ID: 7896540 [TBL] [Abstract][Full Text] [Related]
6. Ifosfamide, cisplatin, and etoposide (ICE) in the treatment of advanced non-small cell lung cancer. Shepherd FA; Evans WK; Goss PE; Latreille J; Logan D; Maroun J; Stewart D; Warner E; Paul K Semin Oncol; 1992 Feb; 19(1 Suppl 1):54-8. PubMed ID: 1329213 [TBL] [Abstract][Full Text] [Related]
7. Cisplatin, ifosfamide, and prolonged oral etoposide in the treatment of patients with extensive small cell lung carcinoma. Glisson B; Lee JS; Palmer J; Fossella F; Shin DM; Murphy WK; Perez-Soler R; Hong WK Cancer; 1998 Jan; 82(2):301-8. PubMed ID: 9445186 [TBL] [Abstract][Full Text] [Related]
8. Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in treatment of newly diagnosed pediatric solid tumors. Marina NM; Rodman JH; Murry DJ; Shema SJ; Bowman LC; Jones DP; Furman W; Meyer WH; Pratt CB J Natl Cancer Inst; 1994 Apr; 86(7):544-8. PubMed ID: 8133538 [TBL] [Abstract][Full Text] [Related]
9. DICE (dexamethasone, ifosfamide, cisplatin, etoposide) infusional chemotherapy for refractory or relapsed non-Hodgkin's lymphoma (NHL). Coleman M; Leonard J; Shuster MW; Kaufman TP Eur J Haematol Suppl; 2001 Jul; 64():41-5. PubMed ID: 11486401 [TBL] [Abstract][Full Text] [Related]
10. A phase II study of ifosfamide in combination with etoposide and cisplatin in the treatment of extensive small cell lung cancer. Evans WK; Stewart D; Logan D; Maroun J; Goss G; Shepherd FA; Latreille J; Warner E; Dahrouge S Semin Oncol; 1992 Dec; 19(6 Suppl 12):51-6. PubMed ID: 1336622 [TBL] [Abstract][Full Text] [Related]
11. High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular Cancer Cooperative Study Group. Siegert W; Beyer J; Strohscheer I; Baurmann H; Oettle H; Zingsem J; Zimmermann R; Bokemeyer C; Schmoll HJ; Huhn D J Clin Oncol; 1994 Jun; 12(6):1223-31. PubMed ID: 7911158 [TBL] [Abstract][Full Text] [Related]
12. Cisplatin and ifosfamide with either vinblastine or etoposide as salvage therapy for refractory or relapsing germ cell tumor patients: the Institut Gustave Roussy experience. Farhat F; Culine S; Théodore C; Békradda M; Terrier-Lacombe MJ; Droz JP Cancer; 1996 Mar; 77(6):1193-7. PubMed ID: 8635143 [TBL] [Abstract][Full Text] [Related]
13. Ifosfamide with mesna uroprotection and etoposide in recurrent, refractory acute leukemia in childhood. A Pediatric Oncology Group Study. Bernstein ML; Whitehead VM; Devine S; Grier H; Kung F; Krischer J; Dreyer Z; Bell B; Land V; Buchanan GR Cancer; 1993 Sep; 72(5):1790-4. PubMed ID: 8348510 [TBL] [Abstract][Full Text] [Related]
14. A Phase I study of granulocyte-macrophage-colony stimulating factor/interleukin-3 fusion protein (PIXY321) following ifosfamide, carboplatin, and etoposide therapy for children with recurrent or refractory solid tumors: a report of the Children's Cancer Group. Cairo MS; Krailo MD; Weinthal JA; Secola R; Bergeron S; van de Ven C; Blazar BR; Garrison L; Reaman GH Cancer; 1998 Oct; 83(7):1449-60. PubMed ID: 9762948 [TBL] [Abstract][Full Text] [Related]
15. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group. Schmoll HJ; Kollmannsberger C; Metzner B; Hartmann JT; Schleucher N; Schöffski P; Schleicher J; Rick O; Beyer J; Hossfeld D; Kanz L; Berdel WE; Andreesen R; Bokemeyer C; J Clin Oncol; 2003 Nov; 21(22):4083-91. PubMed ID: 14568987 [TBL] [Abstract][Full Text] [Related]
16. Ifosfamide/etoposide combination in the treatment of recurrent malignant solid tumors of childhood. A Pediatric Oncology Group Phase II study. Kung FH; Pratt CB; Vega RA; Jaffe N; Strother D; Schwenn M; Nitschke R; Homans AC; Holbrook CT; Golembe B Cancer; 1993 Mar; 71(5):1898-903. PubMed ID: 8448755 [TBL] [Abstract][Full Text] [Related]
17. Phase I study of high-dose cisplatin, ifosfamide, and etoposide. Perez EA; Sowray PC; Gardner SL; Gandara DR Cancer Chemother Pharmacol; 1994; 34(4):331-4. PubMed ID: 8033300 [TBL] [Abstract][Full Text] [Related]
18. Salvage chemotherapy in refractory germ cell tumors with etoposide (VP-16) plus ifosfamide plus high-dose cisplatin. A VIhP regimen. Ghosn M; Droz JP; Theodore C; Pico JL; Baume D; Spielmann M; Ostronoff M; Moran A; Salloum E; Kramar A Cancer; 1988 Jul; 62(1):24-7. PubMed ID: 3133101 [TBL] [Abstract][Full Text] [Related]
19. Combination therapy with carboplatin/cisplatin/ifosfamide/etoposide in ovarian cancer. Lund B; Hansen OP; Hansen HH; Hansen M Semin Oncol; 1992 Feb; 19(1 Suppl 1):26-9. PubMed ID: 1411618 [TBL] [Abstract][Full Text] [Related]
20. Ifosfamide- and etoposide-based chemotherapy as salvage and mobilizing regimens for poor prognosis lymphoma. Mayer J; Vásová I; Korístek Z; Navrátil M; Klabusay M; Doubek M; Vorlícek J; Cernilová I; Vodvárka P; Petráková K Eur J Haematol Suppl; 2001 Jul; 64():21-7. PubMed ID: 11486396 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]